Under the terms of the agreement, BRAIN has access to the EnBase technology, characterized by enzyme based substrate delivery from a polymer layer to the cultivation medium for high throughput screening with expression libraries and commercially relevant microbial host strains. BioSilta gets access to application-relevant process developments on high throughput enzyme discovery and protein expression.
The goal of this collaboration is to co-develop and optimize microwell plate based high cell density protein expression and high throughput enzyme discovery technologies through the application of the advanced cell culture technology platform EnBase. In this strategic collaboration, EnBase shall be implemented into application oriented processes to accelerate enzyme discovery and improve expression of enzymes used for industrial applications.
Jurgen Eck, chief technology officer at BRAIN, said: “We are convinced that the striking EnBase technology of BioSilta will broaden our technology platform and will be of help to increase screening sensitivity leading to higher hit rates and to speed-up development cycles for industrial enzymes and biocatalysts.”